Login to Your Account



AltaRex Plans U.S. Filing Despite Mixed Results Of OvaRex Trials

By Kim Coghill


Monday, January 28, 2002
Despite inconsistent results in Phase IIb trials, Canadian company AltaRex Corp. intends this year to file a rolling biologics license application for its late-stage ovarian cancer drug, OvaRex.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription